Precision BioSciences Q2 2024 GAAP EPS $4.67 Beats $(1.38) Estimate, Sales $49.898M May Not Be Comparable To $8.856M Estimate
Portfolio Pulse from Benzinga Newsdesk
Precision BioSciences reported a Q2 2024 GAAP EPS of $4.67, significantly beating the estimated loss of $(1.38). The company's sales were $49.898 million, which may not be comparable to the estimated $8.856 million.
August 01, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precision BioSciences reported a strong Q2 2024 with a GAAP EPS of $4.67, beating the estimated loss of $(1.38). Sales were $49.898 million, significantly higher than the $8.856 million estimate.
The significant beat in both EPS and sales figures is likely to positively impact Precision BioSciences' stock price in the short term. Investors will view the strong financial performance as a positive indicator of the company's growth and profitability.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100